Mutational analysis of mucopolysaccharidosis type VI patients undergoing a phase II trial of enzyme replacement therapy

• Published in: Molecular genetics and metabolism Vol. 90; no. 2; pp. 164 - 170
• Main Authors: Karageorgos, Litsa, Brooks, Doug A., Harmatz, Paul, Ketteridge, David, Pollard, Anthony, Melville, Elizabeth L., Parkinson-Lawrence, Emma, Clements, Peter R., Hopwood, John J.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.02.2007
• Subjects: Adolescent; Adult; ARSB; Arylsulfatase B; Child; DNA Mutational Analysis; Female; Humans; Male; Maroteaux–Lamy syndrome; MPS VI; Mucopolysaccharidosis IV - drug therapy; Mucopolysaccharidosis IV - genetics; Mucopolysaccharidosis type VI; Mutation; Mutational analysis; N-Acetylgalactosamine-4-Sulfatase - genetics; N-Acetylgalactosamine-4-Sulfatase - therapeutic use; Recombinant Proteins - genetics; Recombinant Proteins - therapeutic use; MPS VI; Arylsulfatase B; Maroteaux–Lamy syndrome; Mutational analysis; ARSB; Mucopolysaccharidosis type VI
• ISSN: 1096-7192; 1096-7206
• DOI: 10.1016/j.ymgme.2006.10.008

Mucopolysaccharidosis type VI (MPS VI; Maroteaux–Lamy syndrome) is a lysosomal storage disorder caused by mutations in the N-acetylgalactosamine-4-sulfatase (ARSB) gene. These mutations result in a deficiency of ARSB activity. Ten MPS VI patients were involved in a phase II clinical study of enzyme replacement therapy. Direct sequencing of genomic DNA from these patients was used to identify ARSB mutations. Each individual exon of the ARSB gene was amplified by PCR and subsequently sequenced. Thirteen substitutions (c.215T>G [p.L72R] c.284G>A [p.R95Q], c.305G>A [p.R102H], c.323G>T [p.G108V], c.389C>T [p.P130L], c.511G>A [p.G171S], c.904G>A [p.G302R], c.944G>A [p.R315Q], c.1057T>C [p.W353R], c.1151G>A [p.S384N], c.1178A>C [p.H393P], c.1289A>G [p.H430R] and c.1336G>C [p.G446R]), one deletion (c.238delG), and two intronic mutations (c.1213+5G>A and c.1214-2A>G) were identified. Nine of the 16 mutations identified were novel (R102H, G108V, P130L, G171S, W353R, H430R, G446R, c.1213+5G>A and c.1214-2A>G). The two common polymorphisms c.1072G>A [p.V358M] and c.1126G>A [p.V376M] were identified in some of the patients, along with the silent mutations c.972A>G and c.1191A>G. Cultured fibroblast ARSB mutant protein and residual activity were determined for each patient and, together with genotype information, used to predict the expected clinical severity of each patient.